Mineralocorticoid Receptor Antagonists
Phase 3Small molecule
Mineralocorticoid Receptor Antagonists is one of 102 small molecule programs targeting Diabetic Nephropathy. It is currently in Phase 3.
3
Indications
3
Total Trials
2
Active Trials
101
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
146 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Primacor
SanofiApproved
Geodon
PfizerApproved
Cardene
Sun Pharmaceutical Industries, Inc.Approved
Camzyos
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Midamor
PPadagis LLC
Approved
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Approved
Colcrys
Jazz PharmaceuticalsPhase 3
Pelacarsen
NovartisPhase 3
Cagrilintide
Novo NordiskPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Primary Aldosteronism1 trial
Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism
Completed·—··NCT03174847·57 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Pennsylvania